Personalized and predictive medicine in Turkey: A symposium report of the Istanbul Working Group on Personalized Medicine, Istanbul, Turkey, September 10-12, 2009

Current Pharmacogenomics and Personalized Medicine

Volumn 7, Issue 4, 2009, Pages 297-301

  Hizel, C ^a,b   Gok S ^c   Sardas S ^d   Bernard Gallon, D ^e   Maugard, C ^f,g   Genc E ^b  

^a C2H Vichy Genomics   (France)

^b YEDITEPE UNIVERSITY   (Turkey)

^c CELAL BAYAR UNIVERSITY   (Turkey)

^d MARMARA UNIVERSITY   (Turkey)

^e CENTRE JEAN PERRIN   (France)

^f Institut du Cancer de Montreal   (Canada)

^g UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

LMICs; Lower and middle income countries; Personalized medicine; Pharmacogenomics guided pharmacovigilance; Regional capacity building

Indexed keywords

14 HYDROXYCLARITHROMYCIN; ANTIDEPRESSANT AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; CLARITHROMYCIN; CYTOCHROME P450; CYTOCHROME P450 2D6; DAIDZEIN; FLUOROURACIL; GEFITINIB; GENISTEIN; GLUCURONOSYLTRANSFERASE 1A1; GUANOSINE TRIPHOSPHATASE; IMATINIB; IRINOTECAN; MERCAPTOPURINE; RAB PROTEIN; RITUXIMAB; TAMOXIFEN; TUBERCULOSTATIC AGENT; XENOBIOTIC AGENT;

ADJUVANT THERAPY; BIOEQUIVALENCE; BREAST CANCER; CANCER CELL CULTURE; COLORECTAL CANCER; CONFERENCE PAPER; CYTOLOGY; DEPRESSION; DIARRHEA; DRUG ACETYLATION; DRUG METABOLISM; DRUG SURVEILLANCE PROGRAM; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC TRAIT; GENETIC VARIABILITY; HEMOLYTIC ANEMIA; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN GENOME PROJECT; INDIVIDUALIZATION; INDUSTRIALIZATION; INFECTION; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; MULTIDRUG RESISTANCE; NEUTROPENIA; NUTRITIONAL HEALTH; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HEALTH; ONCOLOGY; PATIENT CARE; PHARMACOGENETICS; PSYCHIATRY; SYMPOSIUM; SYSTEMS BIOLOGY; TUBERCULOSIS; TURKEY (REPUBLIC); UNSPECIFIED SIDE EFFECT; VICIA FABA;

EID: 73649118477     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/187569209790112373     Document Type: Conference Paper

References (9)

1. Dausset J. The cultural impact of scientific innovations. Predictive medicine and its sociological impact. [Accessed on October 28, 2009]. Available from: http://unesdoc.unesco.org/images/0006/000678/067814eb.pdf
2. Ruffié J. Naissance de la Médecine Prédictive. Paris: Odile Jacob 1993.
3. Zimmern RL. Genomic medicine: the future is now. Lessons for Hong Kong from the House of Lords Report on Genomic Medicine. Hong Kong Med J 2009; 15(5): 324-5.
4. Pang T. Pharmacogenomics and personalized medicine for the developing world -Too soon or just-in-time? A personal view from the World Health Organization. Curr Pharmacogenomics Person Med 2009; 7(3): 149-57.
5. Normile D. Consortium hopes to map human history in Asia. Science 2007; 306(5702): 1667.
6. Sgaier SK, Jha P, Mony P, et al. Biobanks in developing countries: needs and feasibility. Science 2007; 318(5853): 1074-5. [7] Suarez-Kurtz G. Pharmacogenomics in admixed populations: The Brazilian Pharmacogenetics/ pharmacogenomics network - REFARGEN. Pharmacogenomics J 2004; 4: 347-8.
7. Prainsack B, Reardon J, Hindmarsh R, et al. Personal genomes: misdirected precaution. Nature 2008; 456(7218): 34-5.
8. Knoppers BM. Genomics and policymaking: from static models to complex systems? Hum Genet 2009; 125(4): 375-9.
9. Pharmacovigilance Center of Turkey (TUFAM). [Accessed on October 28, 2009]. Available from: http://www.iegm.gov.tr/Default.aspx?sayfa= tufama&lang=tr-TR.